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Newly emerging data highlight obesity as an important risk factor for developing certain
types of cancer, including colorectal cancer. Although evidence supports a link between
the two, the mechanisms responsible for this relationship have not yet been fully eluci-
dated. Hypertrophied and dysfunctional adipose tissue of the obese state is characterized
by low-grade inflammation. Adipokines and cytokines secreted from adipocytes, together
with the abundant availability of lipids from adipocytes in the tumor microenvironment,
promote adhesion, migration, and invasion of tumor cells and support tumor progression
and uncontrolled growth. One of the predisposed targets of the deleterious effects exerted
by secretions from adipose tissue in obesity is the activities associated with the cellular
mitochondria. Mitochondrial oxidative metabolism plays a key role in meeting cells’ ener-
getic demands by oxidative phosphorylation (OxPhos). Here we discuss: (a) the dynamic
relationship between glycolysis, the tricarboxylic acid cycle, and OxPhos; (b) the evidence
for impaired OxPhos (i.e., mitochondrial dysfunction) in colon cancer; (c) the mechanisms
by which mitochondrial dysfunction can predispose to cancer. We propose that impaired
OxPhos increases susceptibility to colon cancer since OxPhos is sensitive to a large num-
ber of factors that are intrinsic to the host (e.g., inflammation). Given that adipocytes are
a major source of adipokines and energy for the cancer cell, understanding the mecha-
nisms of metabolic symbiosis between cancer cells and adipocytes should reveal new
therapeutic possibilities.
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OBESITY AND COLORECTAL CANCER
Cancer is one of the leading causes of death in the developed world.
Colorectal cancer (CRC) is the fourth cause of cancer death, being
the second most common type of cancer in women and the third
most common in men (1). One of the relatively newly discussed
risk factors for CRC is obesity, whose incidence is also accelerating
worldwide (2).
The global obesity epidemic is thought to directly affect the
incidence of CRC, with a 7% increase in CRC risk for every 2.4
unit increase in body-mass index (BMI) (3). Current epidemiolog-
ical studies demonstrate that overweight and obesity can account
for 14% of all cancer-related deaths in men, 20% in women (4).
The results of a meta-analysis also revealed a 5% increased risk of
CRC per inch of waist circumference, an indication of abdominal
fat (5). Due to the excess availability of energy-dense food and
physical inactivity, obesity levels have risen dramatically in west-
ern countries, including the USA (6). Indeed, the prevalence of
obesity, defined by a BMI above 30 kg/m2, has now reached 35%
with no indication of a decline (6).
The increasing prevalence of obesity encourages the perfor-
mance of studies aimed at acquiring an in-depth understanding
of the relationship between obesity and cancer. Identifying the
mechanisms that contribute to the causal association between
obesity and cancer may facilitate a better understanding of this
relationship (2). Whereas there is an abundance of data supporting
a link between obesity and CRC risk, the mechanisms responsible
for this relationship have not yet been fully elucidated. It is crit-
ical to first understand the molecular mechanisms orchestrating
the effects of obesity on CRC, with the aim of developing more
effective therapeutic strategies to combat obesity-associated CRC.
This review summarizes the most recent knowledge of the
mechanisms associated with the cross-reaction between adipose
tissue and the colonic cell. It will try to explain why colonic cells are
more susceptible to developing tumors in an obese environment
(7). To do so, it is imperative to understand the normal colonic
microenvironment in both experimental and human models, and
then elucidate the role played by obesity in cell–cell crosstalk
and delineate the underlying factors contributing to increased
CRC risk.
ADIPOSE TISSUE PHYSIOLOGY IN NON-OBESE INDIVIDUALS
AND ITS PATHOLOGY IN OBESITY
Adipose tissue has conventionally been regarded as an insulat-
ing and mechanically supportive tissue serving mainly for energy
storage. Following the discovery of leptin in 1994, adipose tissue
was considered a fully functioning endocrine organ, capable of
regulating systemic energy and metabolic homeostasis. The active
adipose tissue endocrine organ secretes fatty acids and peptide
hormones or cytokines, collectively termed adipocytokines, which
are directly involved not only in the regulation of whole-body
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metabolism but also in inflammatory and immune responses
(8). These biologically active factors act locally or systemically
to influence multiple processes, including: glucose and fatty acid
metabolism, insulin sensitivity, adipocyte differentiation, inflam-
mation,and the immune response. Adipokines are known to medi-
ate metabolism, chemotaxis, growth, vascularization, coagulation,
and inflammation (8).
The adipose tissue is composed mainly of adipocytes, but also
includes a vascular portion made up of endothelial cells, pericytes,
monocytes, macrophages, and pluripotent stem cells (9, 10). The
anatomical location of the adipose tissue confers specific metabolic
functions (11). Human omental tissue (visceral adipose tissue,
VAT) expresses higher levels of proteins involved in lipid and glu-
cose metabolism than subcutaneous adipose tissue (SAT) depots
(12). Differences in gene expression and lipolytic activity have also
been reported in SAT from the abdomen versus hip anatomical
regions (13). There are notable differences between the amounts
of SAT and VAT present in the abdominal cavity in obese versus
lean subjects. Compared with SAT, VAT is more cellular, vascular,
and innervated, it contains a larger number of inflammatory and
immune cells, lower preadipocyte-differentiation capacity, and a
greater percentage of large adipocytes (14).
Obesity is characterized by excess whole-body energy, which
accumulates as triacylglycerol in the adipocytes. Obesity, particu-
larly visceral obesity (excess VAT), is considered one of the major
risk factors for developing metabolic diseases, including type 2
diabetes, cardiovascular disease, and cancer (15). Due to the signif-
icant endocrine function of the adipose tissue, numerous patholo-
gies result from the dysfunctional adipocytes in obesity. For exam-
ple, the excess fatty acids produced by dysfunctional adipocytes
disrupt the cell membranes of adjacent cells, resulting in endo-
plasmic reticulum stress and mitochondrial damage (16). Obesity
and metabolic syndrome are characterized by chronic energy
surplus that ultimately induces acute deterioration of the adi-
pose tissue’s endocrine function. Adipocytes undergo hypertrophy,
and secrete increasing amounts of proinflammatory adipokines,
including: monocyte chemoattractant protein (MCP)-1, tumor
necrosis factor (TNF)-α, interleukin (IL)-6, IL-8, plasminogen
activator inhibitor (PAI)-1, and leptin (17). This enhanced secre-
tion of a wide variety of proinflammatory and inflammatory
peptides promotes massive penetration of inflammatory cells such
as macrophages, lymphocytes, and others, all of which induce sig-
nificant alterations of the microenvironment within the adipose
tissue. Cumulatively, these events may ultimately lead to a major
change in the cellular distribution of the adipose tissue. While the
inflammatory cell population may be present at up to 5–10% of
total cells in the lean subjects, in the obese subjects it may reach
up to 50% of the total cellular content of the adipose tissue (18).
The substantial infiltration of inflammatory cells into the adipose
tissue of obese subjects induces a stage of chronic inflammation
that not only modifies the local metabolism, but also influences
systemic energy homeostasis (19). Most of the inflammatory cells
in the obese individual’s adipose tissue are activated macrophages
that release a wide variety of proinflammatory cytokines such as
MCP-1, TNF-α, IL-6, IL-8, and others. These secreted cytokines
induce lipolysis in adipocytes while reducing their ability to syn-
thesize triacylglycerols; this induces an elevation in circulating free
fatty acids, ultimately impinging on systemic metabolic homeosta-
sis. These liberated fatty acids may have deleterious effects in many
cells, including colonic cells (20).
ADIPOSE TISSUE AND ADIPOCYTES IN OBESE INDIVIDUALS
SUPPORT TUMORIGENESIS
The role of the adipose tissue in tumor initiation, growth, and
metastasis is considered to be a relatively new area of investigation.
Basic cancer research has traditionally focused on understanding
the contribution of alterations in cancerous epithelial cells. How-
ever, the characteristics of the tissue’s proximal and distal microen-
vironments are proposed to play an integral role in supporting the
proliferation of cancer cells (21, 22). Therefore, it is important to
understand the complex mutual relationships between colon can-
cer cells and adipocytes and how these interactions may alter colon
cancer metabolism and promote carcinogenesis.
As already noted, adipose tissue in the obese state is char-
acterized by chronic inflammation and enriched proportions of
inflammatory cells such as lymphocytes, macrophages, and stro-
mal cells. These inflammatory cells, together with the altered
resident adipocytes, secrete significant amounts of adipokines and
other cytokines, which have been implicated in the promotion of
tumor growth (17). Most of the adipokines secreted by the obese
adipose tissue, including TNF-α, IL-6, IL-8, and MCP-1, among
others, have been implicated in tumor progression (23). Inflam-
matory cells in obese adipose tissue are able to produce reactive
oxygen species (ROS). ROS have been shown to induce mitogenic
activity at low concentrations and they are therefore considered to
be tumor-promoting signaling molecules (24). Chronically higher
levels of both proinflammatory cytokines and ROS in obesity may
promote tumorigenesis. Although it is not exactly clear how the
inflammatory state in the adipose tissue is initiated, one proposed
factor is hypoxia (25). During weight gain and adipose tissue
expansion, some of the adipose tissue cells are pushed far from
the tissue’s blood vessels, causing these cells to become poorly
oxygenated, resulting in localized hypoxia. Hypoxia is known to
activate hypoxia-inducible factor (HIF)-1α, which in turn induces
the infiltration of macrophages and monocytes into the adipose
tissue and thus upregulates the secretion of TNF-α (26). TNF-α
has been shown to support cancer cell proliferation, angiogenesis,
and metastasis (27, 28). One of the canonical proposed mecha-
nisms of TNF-α-induced carcinogenesis is through activation of
the nuclear transcription factor NF-κB by inhibiting the inhibitor
of NF-κB (IκB) (29). Activated NF-κB has been shown to pre-
vent apoptosis and support inflammation-associated cancers (30).
Moreover, both TNF-α and hypoxic conditions induce secretion
of the proinflammatory cytokine IL-6. IL-6 levels are elevated in
obesity and positively correlate with BMI (31), and a role for
IL-6 in tumorigenesis has been demonstrated in IL-6-deficient
animal models that do not develop tumors (32). The enhanced
secretion of inflammatory cytokines during obesity and the corre-
lation of the inflammatory stage to carcinogenesis clearly correlate
the elevated cytokine levels generated during obesity to advanced
carcinogenesis.
Aside from cytokine secretion, the adipose tissue is the
major endocrine organ synthesizing and secreting adipokines.
Adipokines are hormones derived from adipocytes that play a
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key role in energy homeostasis. Obesity not only alters cytokine
secretion but also adipocytokine secretion. As already mentioned,
some adipocytokines such as TNF-α induce increased angiogen-
esis, with angiogenesis being one of the key steps involved in the
development of certain types of cancer, including CRC (33, 34).
Among the adipocyte-derived cytokines, the serum level of lep-
tin is closely related to the amount of adipose tissue in humans
(35). Leptin informs the brain of the body’s energy status through
activation of the leptin receptor and causes adjustments in food
intake (35). Obesity is associated with alterations in leptin regu-
lation; chronic overexpression of leptin induces leptin resistance,
resulting in enhanced levels of circulating leptin. This is similar
to the increased insulin levels seen in insulin resistance, which is
also associated with increased adiposity (36). The close relation-
ship between adiposity and leptin levels suggests that this hor-
mone plays a role in the increased incidence of obesity-associated
cancer. Excessive expression of leptin and/or leptin receptor has
been reported as a risk factor for cancer (37). It has been pro-
posed that obesity-related cancers are due, in part, to changes
in the levels of adipokines secreted by adipocytes, infiltrating
macrophages, or associated stromal cells. Although numerous
adipokines have been identified, only a few have been extensively
studied for their involvement in promoting or inhibiting colon
cancer tumor growth. These include leptin, resistin, adiponectin,
and others (38). Elevated levels of circulating leptin have been
shown to increase the risk of colon cancer (37) and other malig-
nancies. Elevated leptin in cancer has been suggested to have
several protumorigenic effects. Leptin shows mitogenic activity
in cancers of the colon (39) and has mitogenic and antiapop-
totic effects (40). A previous study conducted in our laboratory
demonstrated that leptin affects processes related to colon cancer
initiation and progression in vitro (41). Taken together, the effects
of elevated leptin in obesity can drive CRC tumor growth and
progression.
METABOLIC REPROGRAMING AND CRC
Metabolic reprograming is a common feature in most cancers.
Over 90 years ago, Otto Warburg suggested that during cancer
development, glycolysis increases (42, 43). Warburg proposed that
the metabolic shift toward glycolysis is due to injury of the oxida-
tive phosphorylation (OxPhos) system. In contrast to normal
cells, which rely primarily on mitochondrial OxPhos for ATP
production, most cancer cells rely more heavily on aerobic glycol-
ysis, a phenomenon termed “the Warburg effect” (42, 43). These
observations provided the basis for developing the [18F]2-fluoro-
2′-deoxy-d-glucose-positron emission tomography (FDG-PET)
technique used today for cancer examinations (44). Based on the
Warburg effect, it is predicted that if cells rely more heavily on aer-
obic glycolysis, mitochondrial OxPhos will become dysfunctional.
Integrity of the OxPhos system is critical for optimal energy pro-
duction, but optimal assembly of the OxPhos system is a highly
complex process. Impairments of the OxPhos system are asso-
ciated with respective modifications of cellular redox status and
enhanced production of ROS. Indeed, a large number of studies
indicate that the mitochondria play a key role during tumorigen-
esis [reviewed in Ref. (45)], where they can be dysfunctional due
to defects in the OxPhos process, lower levels of mitochondrial
DNA (mtDNA). Some studies have analyzed mutations in mtDNA,
which is relatively more susceptible to damage than nuclear DNA
(nDNA). It has been estimated that nearly 70% of human CRCs
contain mtDNA mutations (46), and these mutations have been
found in several mitochondrial complex-associated genes. For
example, NDUFA13 (GRIM-19), an essential subunit of complex
I, is downregulated in colon carcinogenesis (47); mutations in
SDHs–complex II subunits, lead to tumorigenesis, and they are
therefore considered to be tumor-suppressor genes; similarly, the
expression level of COX2–complex IV subunit 2, is reduced in
many types of cancers (48). Almost complete loss of complex I
(mostly due to mtDNA mutations) is associated with some tumors,
such as in breast cancer (49). Mutations in subunits NDUFA4 and
NDUFA5 affect complex I function and the metastatic properties
of the breast cancer cell line MDA-MB-231 (50). Downregu-
lated expression of the β-subunit of complex V (β-F1-ATPase) in
cancer is associated with a respective increase in glyceraldehyde-
3-phosphate dehydrogenase activity. Therefore, measurement of
the relative expressions of β-F1-ATPase and glyceraldehyde-3-
phosphate dehydrogenase may have prognostic value for breast
and other cancers (51). Moreover, mtDNA is reduced in can-
cer and impaired mitochondrial metabolism may also play a key
role in cancer development (52, 53). The mechanism may include
increased mitochondrial degradation (mitophagy), lower mito-
chondrial proliferation, or both (52). Ussakli et al. (54) recently
reported that mitochondrial loss precedes the development of dys-
plasia, and that it might be useful in detecting, and potentially
predicting cancer. Cook and Higuchi (53); Cook and Higuchi
(53) recently demonstrated that a decrease in mtDNA is corre-
lated with the progression and aggressiveness of tumor growth.
This phenomenon facilitates the use of mtDNA as a diagnostic
tool for evaluating cancer progression. The decreased expression
of mitochondrial genes may be due to the enhanced oxidative
stress conferred by cancer cells (55).
To date, most studies have focused on the effects of tumor
suppressors and oncogenes on cellular metabolism to explain the
Warburg effect, with the main assumption that metabolic alter-
ations are a consequence of transformation (56). In line with
this assumption, oncogenes were shown to favor glycolysis while
tumor suppressors were associated with induction of oxidative
metabolism (57). Taken together, alterations in the activities of
tumor suppressors and oncogenes during carcinogenesis induce
metabolism reprograming in the transformed cells to supply their
metabolic needs (58). These findings evolved into the hypothesis
that altered metabolism plays a primary role in cancer develop-
ment, rather than being only a marginal event (59). Mutations
in p53 and mtDNA are detected in most cancers, supporting the
notion that mitochondrial dysfunction and cancer development
are closely related (60). For example, mitochondrial dysfunction
may promote cancer development by: (i) activation of AKT and
HIF1α pathways (61, 62), (ii) suppression of p53 and PTEN func-
tion, (iii) induction of resistance to cell death (63), and (iv) a
metabolic shift toward glycolysis (64). Supporting evidence for
this hypothesis was obtained from assessing the expression of gly-
colytic enzymes such as pyruvate kinase (PKM2) and isocitrate
dehydrogenase (IDH1, 2), among others, and demonstrating that
they enhance cellular transformation.
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METABOLIC REPROGRAMING IN OBESITY-ASSOCIATED CRC
Metabolic reprograming has been found to be altered in obesity
(65), and in cancer (66). The question is whether obesity impinges
directly on epithelial cell metabolism and induces the development
of different types of cancer, particularly those of peripheral tissues
that are near the VAT (e.g., liver, colon, pancreas, and kidney).
A reduction in mtDNA has been found in adipocytes from
obese individuals (65). That study demonstrated that mitochon-
dria in white adipose tissue play an important role in energy
metabolism and in the development of obesity, insulin resistance
and, ultimately, type 2 diabetes. Supporting this view, Wilson-
Fritch et al. (67) demonstrated that fat cells from ob/ob mice
display reduced mitochondrial mass and altered mitochondrial
structure, which could be normalized by treatment with the PPAR-
γ agonist rosiglitazone. Lindinger et al. (68) evaluated the mtDNA
content per cell of omental adipose tissue and found that it tended
to be lower in patients with diabetes, which may partly explain
the impairment of mitochondrial function observed in insulin
resistance. The number of mitochondria in white adipocytes is
relatively low. The biogenesis of mitochondria and, thus, their
numbers, are controlled by different extracellular and intracellular
stimuli, a case in point being changes in temperature (69). Cellu-
lar mitochondrial content is also controlled by fission and fusion
processes (70). In cases of mitochondrial stress, mitochondria can
divide or fuse to restore their function. During the fusion process,
mitochondria distribute mitochondrial proteins and exchange
mtDNA; fusion is followed by a fission process, which leads to
newly “renovated” mitochondria. This fusion–fission process may
be dysregulated in obesity (71). Taken together, these findings
support the idea that the mitochondria in adipose tissue play an
important role in energy metabolism and in the development of
obesity and associated diseases.
Mitochondrion-derived proteins, such as NDUFA4L2 (a com-
plex I inhibitor) and the deacetylase SIRT3, among others, are
associated with both carcinogenesis and cellular respiration (72–
74). OxPhos deficiency has been shown to suppress p53 expres-
sion/function in several cell types (75). Mitochondrial dysfunction
caused by extensive mtDNA mutations is suggested to play a key
role in aging and other diseases, including cancer (66). These find-
ings therefore suggest that declining OxPhos function could play
a causative role in increasing cancer incidence with age.
A link between obesity, inflammation, metabolic reprograming,
and cancer was addressed in a study in which chronic inflam-
mation associated with obesity was shown to facilitate cancer
initiation and progression by suppressing OxPhos (76, 77). Garcia-
Ruiz et al. (78) showed that inflammation and oxidative stress
induced by TNF-α are associated with damage to the OxPhos sys-
tem in liver tissue of ob/ob mice. Inflammation can occur through
localized secretion of factors such as TNF-α, Wnt peptides, lep-
tin, etc., all of which can impair OxPhos activity (79). Yadava
et al. (66) showed that mitochondrial complexes I, III, and IV are
affected by inflammatory cytokines. These authors demonstrated
that low concentrations of TNF-α (too low to induce cell death)
significantly reduce the expression levels of the NDUFS3 subunit
FIGURE 1 | Summary of potential interactions between adipocytes
from lean versus obese individuals. Molecules secreted from the adipose
tissue of obese individuals induce mitochondrial dysfunction, which is
associated with carcinogenesis. In contrast, molecules secreted from the
adipose tissue of lean individuals do not alter mitochondrial metabolic
activity in colonocytes.
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of complex I in HEK293 cells. Similarly, treatment of primary
human mammary epithelial cells with TNF-α induced a signifi-
cant reduction in mitochondrial complex I-associated respiration,
which was already detectable within 1 h of exposure to TNF-α.
Wnt proteins can promote the epithelial-to-mesenchymal transi-
tion (EMT) and stem cell-like behavior of colonic epithelial cells
(80). Dickkopf-1 (Dkk1) is a potent inhibitor of Wnt signaling,
and the expression of Dkk1 was reduced in colon cancer, with a
concomitant reduction in immunohistochemical features of EMT
(such as increased expression of the epithelial marker E-cadherin,
decreased expression of the mesenchymal marker vimentin, and
cytoplasmic distribution of β-catenin). Furthermore, Dkk1 over-
expression resulted in restoration of the epithelial phenotype and
decreased expression of EMT transcription factors Snail and Twist,
and decreased the expression of markers of intestinal stem cells
such as cluster of differentiation 133 (CD133) and leucine-rich-
repeat-containing G-protein-coupled receptor 5 (Lgr5). Interest-
ingly, exposure of cancer cells to Wnt proteins has been shown
to inhibit OxPhos as well, and to enhance glycolysis through the
downregulation of complex IV subunits (81). Therefore, inflam-
mation mediated by TNF-α or Wnt proteins may influence cancer
progression though alterations of mitochondrial metabolism.
The effect of adipokines on mitochondrial activity may pro-
vide a link via which adipose tissue secretions can influence the
outcome of colon cancer (see Figure 1). We recently addressed the
issue of metabolic reprograming in obesity-associated CRC and
demonstrated that secreted products from the adipose tissue of
obese subjects inhibit mitochondrial respiration and function in
HCT116 colon cancer cells, an effect that is at least partly mediated
by leptin (82). As already mentioned, leptin is an adipokine that
is synthesized and secreted by the adipose tissue, and its systemic
levels mirror fat adiposity. Leptin is predominantly involved in the
regulation of food intake and energy homeostasis via central activ-
ities (83). In addition, leptin has been shown to exert a wide variety
of effects peripherally, activities associated with the immune sys-
tem, angiogenesis, interaction with signaling pathways of growth
hormones, and lipid metabolism. A vast number of reports sug-
gest that leptin is a legitimate key candidate linking obesity to
carcinogenesis (37, 39, 41, 84). A previous study conducted in
our laboratory supports the view that leptin may directly affect
processes related to colon cancer initiation and progression in
colon cancer cells in vitro (41). Furthermore, in our recent study
(82), we demonstrate that colon cancer cells exposed to condi-
tioned media prepared fromVAT from obese subjects express lower
oxygen consumption rate (OCR) levels than colon cancer cells
exposed to conditioned media obtained from VAT from lean sub-
jects. The lower OCR levels were associated with lower expression
levels of nuclear- and mitochondrion-encoded genes, suggesting
a central role for mitochondria in the metabolic reprograming of
colon cancer by obesity.
CONCLUDING REMARKS
Taken together, the reviewed studies suggest that one of the most
important links between adipose tissue secretions from obese
individuals and colon cancer progression is the mitochondrial dys-
function induced by adipocyte secretions in colonic cells. From our
recent study, we are able to pinpoint the adipokine leptin as one
of the direct links between adipose tissue secretions from obese
subjects. The exact molecular signaling pathways mediating this
effect have yet to be discovered; however, we have previously found
that leptin promotes the metastatic potential of colon cancer cells
by affecting PI3K and Src kinase pathways and activating Rac1 and
Cdc42 (41).
Understanding the molecular mechanisms by which obesity
increases colon cancer risk will help in designing novel strategies
to prevent the increasing number of cases of obesity-related colon
cancer.
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